Grantham Mayo Van Otterloo & Co. LLC grew its position in Bath & Body Works, Inc. (NYSE:BBWI - Free Report) by 3.2% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 412,722 shares of the company's stock after buying an additional 12,781 shares during the period. Grantham Mayo Van Otterloo & Co. LLC owned approximately 0.19% of Bath & Body Works worth $16,001,000 at the end of the most recent quarter.
Other large investors have also made changes to their positions in the company. Fifth Third Wealth Advisors LLC grew its stake in Bath & Body Works by 4.9% in the fourth quarter. Fifth Third Wealth Advisors LLC now owns 6,982 shares of the company's stock valued at $271,000 after acquiring an additional 324 shares during the period. SRS Capital Advisors Inc. grew its position in shares of Bath & Body Works by 99.7% in the 4th quarter. SRS Capital Advisors Inc. now owns 659 shares of the company's stock valued at $26,000 after purchasing an additional 329 shares during the period. TD Private Client Wealth LLC increased its stake in Bath & Body Works by 24.2% during the 3rd quarter. TD Private Client Wealth LLC now owns 1,697 shares of the company's stock worth $54,000 after purchasing an additional 331 shares in the last quarter. UMB Bank n.a. raised its holdings in Bath & Body Works by 58.8% during the 4th quarter. UMB Bank n.a. now owns 905 shares of the company's stock worth $35,000 after buying an additional 335 shares during the period. Finally, Lindbrook Capital LLC lifted its stake in Bath & Body Works by 81.9% in the fourth quarter. Lindbrook Capital LLC now owns 957 shares of the company's stock valued at $37,000 after buying an additional 431 shares in the last quarter. Institutional investors own 95.14% of the company's stock.
Bath & Body Works Price Performance
BBWI stock traded down $1.28 during trading hours on Friday, reaching $26.34. The stock had a trading volume of 2,512,209 shares, compared to its average volume of 4,639,720. The stock has a 50-day simple moving average of $33.24 and a 200 day simple moving average of $34.01. Bath & Body Works, Inc. has a fifty-two week low of $24.96 and a fifty-two week high of $52.99. The stock has a market capitalization of $5.64 billion, a PE ratio of 6.42, a price-to-earnings-growth ratio of 0.92 and a beta of 1.69.
Bath & Body Works (NYSE:BBWI - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The company reported $2.09 EPS for the quarter, topping analysts' consensus estimates of $2.04 by $0.05. The business had revenue of $2.79 billion during the quarter, compared to analysts' expectations of $2.78 billion. Bath & Body Works had a negative return on equity of 44.03% and a net margin of 12.43%. On average, sell-side analysts forecast that Bath & Body Works, Inc. will post 3.3 EPS for the current fiscal year.
Bath & Body Works Announces Dividend
The firm also recently declared a quarterly dividend, which was paid on Friday, March 7th. Shareholders of record on Friday, February 21st were issued a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a yield of 3.04%. The ex-dividend date was Friday, February 21st. Bath & Body Works's dividend payout ratio is 21.98%.
Bath & Body Works declared that its board has approved a stock buyback plan on Thursday, February 27th that authorizes the company to repurchase $500.00 million in outstanding shares. This repurchase authorization authorizes the company to purchase up to 6.4% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company's board of directors believes its shares are undervalued.
Analyst Ratings Changes
Several equities research analysts have recently issued reports on the stock. Argus reissued a "hold" rating on shares of Bath & Body Works in a research report on Friday, January 10th. Cowen reiterated a "buy" rating on shares of Bath & Body Works in a report on Thursday, February 27th. Robert W. Baird lifted their price target on Bath & Body Works from $45.00 to $47.00 and gave the company an "outperform" rating in a research note on Friday, February 28th. TD Cowen upped their price objective on Bath & Body Works from $42.00 to $48.00 and gave the stock a "buy" rating in a research report on Thursday, December 12th. Finally, Barclays decreased their price objective on Bath & Body Works from $43.00 to $38.00 and set an "equal weight" rating for the company in a report on Monday, March 3rd. Four analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $44.06.
Read Our Latest Analysis on Bath & Body Works
Bath & Body Works Company Profile
(
Free Report)
Bath & Body Works, Inc is a specialty retailers and home to America's Favorite Fragrances, offering a breadth of exclusive fragrances for the body and home, including the selling collections for fine fragrance mist, body lotion and body cream, 3-wick candles, home fragrance diffusers and liquid hand soap.
Featured Articles
Before you consider Bath & Body Works, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bath & Body Works wasn't on the list.
While Bath & Body Works currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
